バラシクロビル塩酸塩水和物
バラシクロビル塩酸塩水和物 物理性質
- 融点 :
- 170-172°C
- 貯蔵温度 :
- Keep in dark place,Sealed in dry,Store in freezer, under -20°C
- 溶解性:
- H2O: >20mg/mL
- 外見 :
- 個体
- 色:
- 白い
- 極大吸収波長 (λmax):
- 253nm(H2O)(lit.)
- Merck :
- 14,9899
- 安定性：:
- 吸湿性
- CAS データベース:
- 124832-27-5(CAS DataBase Reference)
安全性情報
- リスクと安全性に関する声明
- 危険有害性情報のコード(GHS)
| 絵表示（GHS） |
|
| 注意喚起語 |
警告 |
| 危険有害性情報 |
| コード |
危険有害性情報 |
危険有害性クラス |
区分 |
注意喚起語 |
シンボル |
P コード |
| H302 |
飲み込むと有害 |
急性毒性、経口 |
4 |
警告 |
|
P264, P270, P301+P312, P330, P501 |
|
| 注意書き |
|
バラシクロビル塩酸塩水和物 価格
もっと(21)
| メーカー |
製品番号 |
製品説明 |
CAS番号 |
包装 |
価格 |
更新時間 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
W01TRCV085000 |
L-バラシクロビル塩酸塩
L-Valacyclovir Hydrochloride |
124832-27-5 |
100mg |
￥36900 |
2024-03-01 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
W01COBQC-5591 |
バラシクロビル塩酸塩 hydrate
Valacyclovir hydrochloride hydrate |
124832-27-5 |
100mg |
￥85000 |
2024-03-01 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
W01COBQC-5591 |
バラシクロビル塩酸塩 hydrate
Valacyclovir hydrochloride hydrate |
124832-27-5 |
1g |
￥105000 |
2024-03-01 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
W01COBQC-5591 |
Valacyclovir hydrochloride hydrate |
124832-27-5 |
5g |
￥365000 |
2024-03-01 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
W01TRCV085000 |
L-バラシクロビル塩酸塩
L-Valacyclovir Hydrochloride |
124832-27-5 |
500mg |
￥60800 |
2023-06-01 |
購入 |
バラシクロビル塩酸塩水和物 化学特性,用途語,生産方法
外観
白色～うすい黄色, 結晶性粉末～粉末
溶解性
水に可溶
用途
逆転写酵素阻害剤です。逆転
写酵素を阻害し、DNA 鎖の伸長を停止するこ
とによりウイルスの増殖を抑制します。
効能
抗ウイルス薬, DNAポリメラーゼ阻害薬
商品名
バルトレックス (グラクソ・スミスクライン); バルトレックス (グラクソ・スミスクライン)
説明
Valacyclovir hydrochloride, an orally active L-valyl ester of the potent antiviral agent aciclovir, was launched in 1995 in the United Kingdom for the treatment of herpes simplex virus (HSV) infections of the skin and mucous membranes, including initial and recurrent genital herpes. As a prodrug, valaciclovir has an improved pharmacokinetic profile to aciclovir. It is rapidly absorbed after oral administration and extensively converted to aciclovir via first-pass metabolism to achieve plasma levels of aciclovir comparable to those seen with aciclovir via i.v. route. Valacyclovir is then activated selectively in virus-infected cells by viral thymidine kinase to form aciclovir triphosphate in a stepwise fashion. This active species inhibits viral DNA polymerase via irreversible binding to the active site of the enzyme. Once aciclovir is incorporated into the elongating viral DNA, it terminates replication of the viral DNA strand, an antiviral mechanism unique to aciclovir. Valacyclovir is reportedly in clinical trials for the suppression of cytomegalovirus infection and disease in renal transplant patients.
化学的特性
White Crystalline Powder
使用
Acyclovir (A192400) impurity. The L-Valine ester prodrug of Acyclovir.
一般的な説明
Valacyclovir (Valtrex) is the hydrochloride salt of the Lvalylester of acyclovir. The compound is a water-solublecrystalline solid, and it is a prodrug intended to increase thebioavailability of acyclovir by increasing lipophilicity.Valacyclovir is hydrolyzed rapidly and almost completely toacyclovir following oral administration.
Valacyclovir has been approved for the treatment of herpeszoster (shingles) in immunocompromised patients. Theside effect profile observed in valacyclovir is comparablewith bioequivalent doses of acyclovir.
薬物動態学
The binding of valacyclovir to human plasma proteins ranges between 13.5 to 17.9%. The plasma elimination half-life of acyclovir is 2.5 to 3.3 hours. The bioavailability of valacyclovir hydrochloride is 54%, compared to approximately 20% for oral acyclovir, and it is as effective as acyclovir in decreasing the duration of pain associated with posttherapeutic neuralgia and episodes of genital lesion healing.
副作用
The adverse effects are similar to acyclovir, which include nausea, headache, vomiting, constipation, and anorexia.
バラシクロビル塩酸塩水和物 上流と下流の製品情報
原材料
準備製品
バラシクロビル塩酸塩水和物 生産企業
Global( 545)Suppliers
バラシクロビル塩酸塩水和物 スペクトルデータ(1HNMR)
124832-27-5(バラシクロビル塩酸塩水和物)キーワード:
- 124832-27-5
- 2-[(2-azanyl-6-oxo-3H-purin-9-yl)methoxy]ethyl (2S)-2-azanyl-3-methyl-butanoate hydrochloride
- L-Valacyclovir Hydrochloride
- Valacyclovir Hydrochloride (200 mg)
- L-Valine, 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]ethyl ester, monohydrochloride (9CI)
- VALACYCLOVIR HYDROCHLORIDE [9-((2-HYDROXY-ETHOXY)MET HYL)GUANINE L-VALINE ESTER HYDROCHLORIDE]
- (S)-2-((2-AMINO-6-OXO-1H-PURIN-9(6H)-YL)METHOXY)ETHYL 2-AMINO-3-METHYLBUTANOATE HYDROCHLORIDE
- 9-((2-Hydroxy-ethoxy)methyl)guanine L-valine ester hydrochloride
- (2S)-2-amino-3-methyl-butyric acid 2-[(2-amino-6-keto-3H-purin-9-yl)methoxy]ethyl ester hydrochloride
- 2-[(2-amino-6-oxo-3H-purin-9-yl)methoxy]ethyl (2S)-2-amino-3-methylbutanoate hydrochloride
- L-VALINE 2-[(2-AMINO-1,6-DIHYDRO-6-OXO-9H-PURIN-9YL)METHOXY]ETHYL ESTER, HYDROCHLORIDE SALT
- VALACV
- VALACYCLOVIR HYDROCHLORIDE
- L-Valine 2-[(2-AMino-1,6-dihydro-6-oxo-9H-purin-9yl)Methoxy]ethyl Ester Hydrochlroride Salt
- Zelitrex
- L-Valine 2-(2-Amino-1,6-dihydro-6-oxo-9H-purin-9-ylmethoxy)ethyl Ester Hydrochloride
- L-Valine-2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]ethyl ester, hydrochloride (1:1)
- Valaciclovir hydrochloride (anhydrous)
- Valaciclovir for system suitability
- 2-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)ethyl ester monohydrochloride
- L-Valacyclovir HCl
- (S)-2-[(2-Amino-6-oxo-6,9-dihydro-3H-purin-9-yl)methoxy]ethyl-2-amino-3-methylbutanoate
- Valaciclovir Hydrochloride Tablets\n
- VALACICLOVIR HCL 99%
- VALACICLOVIR HYDROCHLORIDE,98.0+%
- VALACYCLOVER HYDROCHLORIC 98+%
- L-VALINE -2-[(2-AMINO-1,6-DIHYDRO-6-OXO-9H-PURIN-9-YL) METHOXY]ETHYLESTER MONOHYDROCHLORIDE
- Valacycloverhydrochloride
- L-Valine 2-[(2-Amino-1,6-dihydro-6-oxo-9H-purin-9yl)methoxy]ethyl Ester, Hydrochlroride Salt, ValACV
- VALACYCLOVER HYDROCHLORIC
- 256U
- バラシクロビル塩酸塩水和物
- L-バリン2-(2-アミノ-1,6-ジヒドロ-6-オキソ-9H-プリン-9-イルメトキシ)エチル塩酸塩水和物
- バラシクロビル塩酸塩
- L-バラシクロビル塩酸塩
- バラシクロビル塩酸塩 HYDRATE
- バラシクロビル 塩酸塩 水和物
- 塩酸バラシクロビル
- バラシクロビル塩酸塩 (JP17)
- L-バリン=2-(2-アミノ-1,6-ジヒドロ-6-オキソ-9H-プリン-9-イルメトキシ)エチル=一塩酸塩
- バルトレックス
- L-バリン2-(2-アミノ-1,6-ジヒドロ-6-オキソ-9H-プリン-9-イルメトキシ)エチル・塩酸塩
- バラシクロビル・塩酸